{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:43:29Z","timestamp":1782920609908,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K16923 and JP24K10953"],"award-info":[{"award-number":["JP20K16923 and JP24K10953"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K19467, JP20H00528, JP21K19405, JP23K18264, JP24H00628, and JP25K22609"],"award-info":[{"award-number":["JP18K19467, JP20H00528, JP21K19405, JP23K18264, JP24H00628, and JP25K22609"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004053","name":"Masato Kawano Memorial Public Interest Foundation for Promotion of Pediatrics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19cm0106509, JP22ana221505, JP23ama221505, JP24ama221531, JP25ama221531, and JP19ck0106468"],"award-info":[{"award-number":["JP19cm0106509, JP22ana221505, JP23ama221505, JP24ama221531, JP25ama221531, and JP19ck0106468"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Minimally differentiated acute myeloid leukemia (AML-M0) is a rare and therapeutically challenging subgroup of AML characterized by immature hematopoietic stem cell-like features. To uncover the molecular basis, we conducted a comprehensive multi-omics analysis of 23 pediatric AML-M0 cases and compared them with 1483 leukemia samples. AML-M0 formed a characteristic group that exhibited global DNA hypermethylation and transcriptional suppression, particularly downregulation of genes related to oxidative phosphorylation and ribosome assembly compared to non-M0 AML. Genomic profiling revealed frequent loss-of-function alterations in\n                    <jats:italic>RUNX1<\/jats:italic>\n                    (26%) and\n                    <jats:italic>ETV6<\/jats:italic>\n                    (22%), along with activating mutations in signaling pathways (83%), such as\n                    <jats:italic>RAS<\/jats:italic>\n                    ,\n                    <jats:italic>FLT3<\/jats:italic>\n                    , and\n                    <jats:italic>JAK<\/jats:italic>\n                    . Notably,\n                    <jats:italic>RUNX1<\/jats:italic>\n                    alterations were significantly associated with a poor prognosis. Functional analyses using a CRISPR\/Cas9-mediated\n                    <jats:italic>RUNX1<\/jats:italic>\n                    knockout in a pediatric AML-M0 cell line showed stem cell-like transcriptional features and reduced expression of genes related to oxidative phosphorylation and ribosomal pathways.\n                    <jats:italic>RUNX1<\/jats:italic>\n                    disruption was also associated with reduced in vitro sensitivity to multiple drugs, including cytarabine and anthracyclines. Our study provides the most comprehensive molecular characterization of pediatric AML-M0 to date and identifies\n                    <jats:italic>RUNX1<\/jats:italic>\n                    alterations as important biological and clinical determinants. These insights highlight the potential strategies for precision therapy, including hypomethylating agents, signaling inhibitors, and metabolic targeting, to improve outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-02967-6","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:48:09Z","timestamp":1777448889000},"page":"1427-1438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0472-4663","authenticated-orcid":false,"given":"Tatsuya","family":"Kamitori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-3539","authenticated-orcid":false,"given":"Satoshi","family":"Saida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-4138","authenticated-orcid":false,"given":"Shinichi","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-5414","authenticated-orcid":false,"given":"Nobuyuki","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3723-8445","authenticated-orcid":false,"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuteru","family":"Hiwatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-1787","authenticated-orcid":false,"given":"Ko","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-4978","authenticated-orcid":false,"given":"Katsuyoshi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-4766","authenticated-orcid":false,"given":"Takashi","family":"Taga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6935-5120","authenticated-orcid":false,"given":"Hirohito","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-4960","authenticated-orcid":false,"given":"Itaru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-2011","authenticated-orcid":false,"given":"Katsutsugu","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-7007","authenticated-orcid":false,"given":"Daisuke","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2452-6520","authenticated-orcid":false,"given":"Junko","family":"Takita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2967_CR1","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1182\/blood.V70.5.1400.1400","volume":"70","author":"EJ Lee","year":"1987","unstructured":"Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA. Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood. 1987;70:1400\u20136.","journal-title":"Blood"},{"key":"2967_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2141.1991.tb04444.x","volume":"78","author":"JM Bennett","year":"1991","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol. 1991;78:325\u20139.","journal-title":"Br J Haematol"},{"key":"2967_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2967_CR4","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1182\/blood-2005-11-025536","volume":"109","author":"D Barbaric","year":"2007","unstructured":"Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, Barnard DR, et al. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children\u2019s Oncology Group, studies CCG-2891 and CCG-2961. Blood. 2007;109:2314\u201321.","journal-title":"Blood"},{"key":"2967_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.V83.6.1619.1619","volume":"83","author":"R Stasi","year":"1994","unstructured":"Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood. 1994;83:1619\u201325.","journal-title":"Blood"},{"key":"2967_CR6","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1200\/JCO.19.00327","volume":"37","author":"JE Rubnitz","year":"2019","unstructured":"Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, et al. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: The AML08 multicenter, randomized phase III trial. J Clin Oncol. 2019;37:2072\u201381.","journal-title":"J Clin Oncol"},{"key":"2967_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2013-03-491621","volume":"122","author":"A Pession","year":"2013","unstructured":"Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122:170\u20138.","journal-title":"Blood"},{"key":"2967_CR8","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3324\/haematol.2009.009324","volume":"94","author":"FP Silva","year":"2009","unstructured":"Silva FP, Almeida I, Morolli B, Brouwer-Mandema G, Wessels H, Vossen R, et al. Genome-wide molecular analysis of minimally differentiated acute myeloid leukemia. Haematologica. 2009;94:1546\u201354.","journal-title":"Haematologica"},{"key":"2967_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/leu.2008.34","volume":"22","author":"FP Silva","year":"2008","unstructured":"Silva FP, Morolli B, Storlazzi CT, Zagaria A, Impera L, Klein B, et al. ETV6 mutations and loss in AML-M0. Leukemia. 2008;22:1639\u201343.","journal-title":"Leukemia"},{"key":"2967_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neo.2014.06.002","volume":"16","author":"HW Kao","year":"2014","unstructured":"Kao HW, Liang DC, Wu JH, Kuo MC, Wang PN, Yang CP, et al. Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia. Neoplasia. 2014;16:481\u20138.","journal-title":"Neoplasia"},{"key":"2967_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","volume":"56","author":"M Umeda","year":"2024","unstructured":"Umeda M, Ma J, Westover T, Ni Y, Song G, Maciaszek JL, et al. A new genomic framework to categorize pediatric acute myeloid leukemia. Nat Genet. 2024;56:281\u201393.","journal-title":"Nat Genet"},{"key":"2967_CR12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/cancers14081873","volume":"14","author":"E Genesca","year":"2022","unstructured":"Genesca E, la Starza R. Early T-cell precursor ALL and beyond: immature and ambiguous lineage T-ALL subsets. Cancers. 2022;14:1873.","journal-title":"Cancers"},{"key":"2967_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","volume":"562","author":"TB Alexander","year":"2018","unstructured":"Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562:373\u20139.","journal-title":"Nature"},{"key":"2967_CR14","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1182\/bloodadvances.2021006383","volume":"6","author":"K Kudo","year":"2022","unstructured":"Kudo K, Kubota Y, Toki T, Kanezaki R, Kobayashi A, Sato T, et al. Childhood acute myeloid leukemia with 5q deletion and HNRNPH1-MLLT10 fusion: the first case report. Blood Adv. 2022;6:3162\u20136.","journal-title":"Blood Adv"},{"key":"2967_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41375-023-02075-9","volume":"38","author":"D Tomizawa","year":"2024","unstructured":"Tomizawa D, Matsubayashi J, Iwamoto S, Hiramatsu H, Hasegawa D, Moritake H, et al. High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia. Leukemia. 2024;38:202\u20136.","journal-title":"Leukemia"},{"key":"2967_CR16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12185-017-2395-x","volume":"107","author":"A Shimada","year":"2018","unstructured":"Shimada A, Iijima-Yamashita Y, Tawa A, Tomizawa D, Yamada M, Norio S, et al. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. Int J Hematol. 2018;107:586\u201395.","journal-title":"Int J Hematol"},{"key":"2967_CR17","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1182\/bloodadvances.2019000404","volume":"3","author":"N Shiba","year":"2019","unstructured":"Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, et al. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv. 2019;3:3157\u201369.","journal-title":"Blood Adv"},{"key":"2967_CR18","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1182\/bloodadvances.2019001307","volume":"4","author":"H Ueno","year":"2020","unstructured":"Ueno H, Yoshida K, Shiozawa Y, Nannya Y, Iijima-Yamashita Y, Kiyokawa N, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020;4:5165\u201373.","journal-title":"Blood Adv"},{"key":"2967_CR19","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.3900","volume":"49","author":"M Seki","year":"2017","unstructured":"Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y, et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet. 2017;49:1274\u201381.","journal-title":"Nat Genet"},{"key":"2967_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T Jr., Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103\u201312.","journal-title":"Nat Med"},{"key":"2967_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","volume":"51","author":"Z Gu","year":"2019","unstructured":"Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51:296\u2013307.","journal-title":"Nat Genet"},{"key":"2967_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211\u20138.","journal-title":"Nat Genet"},{"key":"2967_CR23","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"2967_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"2967_CR25","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12:e1004873.","journal-title":"PLoS Comput Biol"},{"key":"2967_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"2967_CR27","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2967_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"2967_CR29","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739\u201340.","journal-title":"Bioinformatics"},{"key":"2967_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"2967_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 2013;14:7.","journal-title":"BMC Bioinforma"},{"key":"2967_CR32","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1093\/bioinformatics\/btx513","volume":"33","author":"Y Tian","year":"2017","unstructured":"Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics. 2017;33:3982\u20134.","journal-title":"Bioinformatics"},{"key":"2967_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nmeth.2810","volume":"11","author":"B Wang","year":"2014","unstructured":"Wang B, Mezlini AM, Demir F, Fiume M, Tu Z, Brudno M, et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods. 2014;11:333\u20137.","journal-title":"Nat Methods"},{"key":"2967_CR34","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572\u20133.","journal-title":"Bioinformatics"},{"key":"2967_CR35","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s12185-025-03929-x","volume":"121","author":"J Ikeda","year":"2025","unstructured":"Ikeda J, Shiba N, Kato S, Kunimoto H, Saito Y, Sagisaka M, et al. Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities. Int J Hematol. 2025;121:694\u2013705.","journal-title":"Int J Hematol"},{"key":"2967_CR36","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00280-020-04045-9","volume":"85","author":"H Goto","year":"2020","unstructured":"Goto H, Yoshino Y, Ito M, Nagai J, Kumamoto T, Inukai T, et al. Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2020;85:773\u201383.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2967_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41375-019-0604-8","volume":"34","author":"AH Elsayed","year":"2020","unstructured":"Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, et al. A six-gene leukemic stem cell score identifies high-risk pediatric acute myeloid leukemia. Leukemia. 2020;34:735\u201345.","journal-title":"Leukemia"},{"key":"2967_CR38","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/bloodadvances.2021005381","volume":"6","author":"G Yamato","year":"2022","unstructured":"Yamato G, Kawai T, Shiba N, Ikeda J, Hara Y, Ohki K, et al. Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia. Blood Adv. 2022;6:3207\u201319.","journal-title":"Blood Adv"},{"key":"2967_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.71","volume":"4","author":"S Weber","year":"2014","unstructured":"Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, et al. BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. Blood Cancer J. 2014;4:e173.","journal-title":"Blood Cancer J"},{"key":"2967_CR40","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.stem.2021.03.023","volume":"28","author":"B Dannenmann","year":"2021","unstructured":"Dannenmann B, Klimiankou M, Oswald B, Solovyeva A, Mardan J, Nasri M, et al. iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia. Cell Stem Cell. 2021;28:906\u2013922.e906.","journal-title":"Cell Stem Cell"},{"key":"2967_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433\u20137.","journal-title":"Nature"},{"key":"2967_CR42","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.stem.2016.10.019","volume":"19","author":"M Farlik","year":"2016","unstructured":"Farlik M, Halbritter F, M\u00fcller F, Choudry FA, Ebert P, Klughammer J, et al. DNA methylation dynamics of human hematopoietic stem cell differentiation. Cell Stem Cell. 2016;19:808\u201322.","journal-title":"Cell Stem Cell"},{"key":"2967_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.stem.2017.04.011","volume":"20","author":"L Garcia-Prat","year":"2017","unstructured":"Garcia-Prat L, Sousa-Victor P, Munoz-Canoves P. Proteostatic and metabolic control of stemness. Cell Stem Cell. 2017;20:593\u2013608.","journal-title":"Cell Stem Cell"},{"key":"2967_CR44","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s12185-013-1347-3","volume":"97","author":"M Ichikawa","year":"2013","unstructured":"Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N, Kurokawa M. A role for RUNX1 in hematopoiesis and myeloid leukemia. Int J Hematol. 2013;97:726\u201334.","journal-title":"Int J Hematol"},{"key":"2967_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12185-017-2259-4","volume":"106","author":"S Feurstein","year":"2017","unstructured":"Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017;106:189\u201395.","journal-title":"Int J Hematol"},{"key":"2967_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-784","volume":"15","author":"S Feurstein","year":"2014","unstructured":"Feurstein S, R\u00fccker FG, Bullinger L, Hofmann W, Manukjan G, G\u00f6hring G, et al. Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. BMC Genomics. 2014;15:784.","journal-title":"BMC Genomics"},{"key":"2967_CR47","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2011.40.6652","volume":"30","author":"JH Mendler","year":"2012","unstructured":"Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012;30:3109\u201318.","journal-title":"J Clin Oncol"},{"key":"2967_CR48","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/leu.2016.126","volume":"30","author":"VI Gaidzik","year":"2016","unstructured":"Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30:2160\u20138.","journal-title":"Leukemia"},{"key":"2967_CR49","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1182\/blood-2009-05-223784","volume":"114","author":"JL Tang","year":"2009","unstructured":"Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, et al. AML1\/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114:5352\u201361.","journal-title":"Blood"},{"key":"2967_CR50","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1182\/blood-2017-11-814442","volume":"131","author":"G Yamato","year":"2018","unstructured":"Yamato G, Shiba N, Yoshida K, Hara Y, Shiraishi Y, Ohki K, et al. RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. Blood. 2018;131:2266\u201370.","journal-title":"Blood"},{"key":"2967_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.stem.2015.06.002","volume":"17","author":"X Cai","year":"2015","unstructured":"Cai X, Gao L, Teng L, Ge J, Oo ZM, Kumar AR, et al. Runx1 deficiency decreases ribosome biogenesis and confers stress resistance to hematopoietic stem and progenitor cells. Cell Stem Cell. 2015;17:165\u201377.","journal-title":"Cell Stem Cell"},{"key":"2967_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1244280","volume":"13","author":"L Feng","year":"2023","unstructured":"Feng L, Zhang PY, Gao W, Yu J, Robson SC. Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia. Front Oncol. 2023;13:1244280.","journal-title":"Front Oncol"},{"key":"2967_CR53","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood.2024024837","volume":"145","author":"Y Liu","year":"2025","unstructured":"Liu Y, Bollino DR, Bah OM, Strovel ET, Le TV, Zarrabi J, et al. A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia. Blood. 2025;145:486\u201396.","journal-title":"Blood"},{"key":"2967_CR54","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"139","author":"CP Mill","year":"2022","unstructured":"Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, et al. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022;139:907\u201321.","journal-title":"Blood"},{"key":"2967_CR55","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859\u201366.","journal-title":"Nat Med"},{"key":"2967_CR56","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2016-10-687830","volume":"129","author":"R Sood","year":"2017","unstructured":"Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017;129:2070\u201382.","journal-title":"Blood"},{"key":"2967_CR57","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41375-019-0605-7","volume":"34","author":"S Saida","year":"2020","unstructured":"Saida S, Zhen T, Kim E, Yu K, Lopez G, McReynolds LJ, et al. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice. Leukemia. 2020;34:759\u201370.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02967-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02967-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02967-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:43:45Z","timestamp":1782917025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02967-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2967"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02967-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}